Robert Barrow
CEO at Definium Therapeutics, Inc. (DFTX); CEO at Mind Medicine (MindMed) Inc. (DFTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $4.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 29SEC | DFTXDefinium Therapeutics, Inc. | Sell Plan | 31,5502,213,090 held (−1%) | $36.57 | $1.2M | +0.9% |
| Sep 4SEC | DFTXDefinium Therapeutics, Inc. | Sell Plan | 19,0231,494,640 held (−1%) | $37.94 | $722K | -2.7% |
| Jun 26SEC | DFTXDefinium Therapeutics, Inc. | Sell Plan | 29,2081,098,246 held (−3%) | $45.03 | $1.3M | -18.1% |
| Mar 26SEC | DFTXDefinium Therapeutics, Inc. | Sell Plan | 24,431752,454 held (−3%) | $18.47 | $451K | +99.8% |
| Dec 29SEC | DFTXMind Medicine (MindMed) Inc. | Sell Plan | 25,791778,477 held (−3%) | $13.15 | $339K | +180.6% |
- Sell
CEO Robert Barrow sold $1.2M of DFTX at $36.57 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Robert Barrow sold $722K of DFTX at $37.94 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Robert Barrow sold $1.3M of DFTX at $45.03 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Robert Barrow sold $451K of DFTX at $18.47 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Robert Barrow sold $339K of DFTX at $13.15 — pre-scheduled 10b5-1 plan sale.